Exploring new perspectives to make extraordinary discoveries

Mission

At Montara, we’re developing safer, more efficacious therapies to improve the lives of patients with central nervous system (CNS) diseases.

Our mission is to create innovative therapies for diseases of the CNS, with a focus on precision medicine and genetically validated targets to enhance drug safety and efficacy.

Science

Precision pharmacology

Our platform enables us to utilize established and novel chemophores, accelerating drug development. We leverage human genetics to identify targets and utilize machine learning to speed preclinical development.

Our platform enables us to utilize established and novel chemophores, accelerating drug development. We leverage human genetics to identify targets and utilize machine learning to speed preclinical development.

Safety and efficacy

By increasing the therapeutic index, we will improve CNS efficacy.

Access to undruggable targets

Through our approach, we can reach previously inaccessible targets for various neurological disorders, including neurodegenerative diseases.

Exciting partnering opportunities

Incorporating existing drugs into our platform opens many partner collaboration opportunities.

About

Solid experience with a fresh perspective

About

Solid experience with a fresh perspective

We are Montara Therapeutics, a San Francisco–based precision-medicine neuroscience biotech startup. Our team boasts significant experience from successful biotech firms such as Mitokinin, Denali, and Soteria, supported by a world-class Scientific Advisory Board (SAB).

We bring a new approach to tackling challenging established targets, along with unique experience in developing enzyme activators and domain expertise in mitophagy.

  • Leadership 

    Nicholas T. Hertz, PhD

    Founder and CEO

    Rishi Rakhit, PhD

    VP of Pharmacology

    Randall Chin, PhD

    VP of Discovery

    Zachary Hill, PhD

    VP of Discovery Chemistry

    Max Lebovitz, MBA

    VP of Business Operations

  • Scientific Advisory Board 

    Kevan Shokat, PhD

    Co-Scientific Founder & SAB Chair

    Thomas Südhof, MD

    Co-Scientific Founder & SAB Member

    Martin Kampmann, PhD

    Co-Scientific Founder & SAB Member

       
    Michael Keiser, PhD

    SAB Member

       
    Miratul Muqit, PhD

    SAB Member

       

Leadership: Proven Track Record

Previous success in developing a potentially disease-modifying Parkinson’s Disease preclinical candidate

Recent successful acquisition of Mitokinin, whose scientific founders were Nicholas Hertz and Kevin Shokat

Publications include Cell, Journal of Biological Chemistry, Proceedings of the National Academy of Sciences, multiple Nature journals, Neuron and others

SAB: Deep Capabilities in Neurodegeneration

Includes members of the National Academy of Sciences and Medicine, a Sjöberg Laureate, a Nobel Laureate, and an NIH New Innovator and Rainwater Prize recipient

Inventors of “drugs for the undruggable,” such as KRAS and PINK1

Expertise in synapse transmission and formation and their importance in Alzheimer’s Disease

Pioneering work in functional genomic CRISPR screens in the relevant cell types for neurodegeneration, including neurons, astrocytes, and microglia

Contact

Get in touch with Montara

Learn more about opportunities with us, and sign up to receive news and updates.

Contact

Get in touch with Montara

Learn more about opportunities with us, and sign up to receive news and updates.


Message frequency may vary. You may opt out at any time. Privacy Policy and Terms of Use

Contact

Get in touch with Montara

Learn more about opportunities with us, and sign up to receive news and updates.


Message frequency may vary. You may opt out at any time. Privacy Policy and Terms of Use